-- European equities traded in the US as American depositary receipts were tracking higher late Friday morning, gaining 0.75% to 1,828.19 on the S&P Europe Select ADR Index, which is up 4% for the week.
From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and lender Banco Bilbao Vizcaya Argentaria (BBVA), which climbed 6.6% and 2% respectively. They were followed by health-tech conglomerate Royal Philips (PHG) and biopharmaceutical company Grifols (GRFS), which rose 1.6% and 1.4% respectively.
The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and internet browser company Opera (OPRA), which fell 2.7% and 2.5% respectively. They were followed by internet advertising firm Criteo (CRTO) and pharmaceutical company Ascendis Pharma (ASND), which dropped 1.8% and 1.4% respectively.
The gainers from the UK were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which advanced 5.1% and 4.3% respectively. They were followed by biotech company Trinity Biotech (TRIB) and medical device maker Smith & Nephew (SNN), which were up 2.3% and 2.1% respectively.
The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and software firm Endava (DAVA), which lost 4.6% and 2.1% respectively. They were followed by biopharmaceutical companies Akari Therapeutics (AKTX) and Amarin (AMRN), which were down 1.9% and 1.5% respectively.